speb/financial-data huggingface dataset:
PHARM.AS cash_flow (quarterly, 2025-12-31) — Issuance Of Debt: 0.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Leases: 6403000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Leases: 6403000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 14351000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 14351000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Long Term Debt: 92719000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 92719000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 107070000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 107070000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 0.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Long Term Debt Issuance: 0.00
PHARM.AS cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -4245000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: -1368000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Long Term Equity Investment: 1944000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Long Term Equity Investment: 1944000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 19935000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 19935000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Minority Interest: 0.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Minority Interest: 0.00
PHARM.AS income_statement (annual, 2025-12-31) — Minority Interests: 313000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: -58215000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: -8000.00
PHARM.AS income_statement (annual, 2025-12-31) — Net Income: 2851000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Net Income: 5300000.00
PHARM.AS income_statement (annual, 2025-12-31) — Net Income Common Stockholders: 2851000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 5300000.00
PHARM.AS income_statement (annual, 2025-12-31) — Net Income Continuous Operations: 2538000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 5300000.00
PHARM.AS income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 2851000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 5300000.00
PHARM.AS income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 2851000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 5300000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: 12847000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: 4798000.00
PHARM.AS income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: 2538000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 5300000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -6000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Net Intangibles Purchase And Sale: 0.00
PHARM.AS income_statement (annual, 2025-12-31) — Net Interest Income: -8739000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Net Interest Income: -1400000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: 85223000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: 233000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -4245000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -1368000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -4245000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -1368000.00
PHARM.AS income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: -8739000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -1400000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -7876000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: 0.00
PHARM.AS cash_flow (annual, 2025-12-31) — Net Other Investing Changes: -1000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Net PPE: 23971000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Net PPE: 23971000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 141564000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 141564000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Non Current Deferred Assets: 31017000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Assets: 31017000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 31017000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 31017000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Non Current Prepaid Assets: 94000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Non Current Prepaid Assets: 94000.00
PHARM.AS income_statement (annual, 2025-12-31) — Normalized EBITDA: 36276000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 9406000.00
PHARM.AS income_statement (annual, 2025-12-31) — Normalized Income: 3959548.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Normalized Income: 5300000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Operating Cash Flow: 54708000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 10707000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Operating Gains Losses: -4356000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: -4626000.00
PHARM.AS income_statement (annual, 2025-12-31) — Operating Income: 20881000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Operating Income: 2000000.00
PHARM.AS income_statement (annual, 2025-12-31) — Operating Revenue: 376134000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Operating Revenue: 106500000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 701680440.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 701680440.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Other Current Assets: 1000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 1000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Other Current Borrowings: 5336000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Other Current Borrowings: 5336000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Other Current Liabilities: -1000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: -1000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: 28819000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: 28819000.00
PHARM.AS income_statement (annual, 2025-12-31) — Other Gand A: 18274000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Other Gand A: 20000000.00
PHARM.AS income_statement (annual, 2025-12-31) — Other Income Expense: 704000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Other Income Expense: 4200000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 132219000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 132219000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Other Non Cash Items: 13380000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 2291000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 1228000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 1228000.00
PHARM.AS income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 1575000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 4200000.00
PHARM.AS income_statement (annual, 2025-12-31) — Other Operating Expenses: 82742000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Other Properties: 6115000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Other Properties: 6115000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Other Receivables: 1932000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Other Receivables: 1932000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 33796000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 33796000.00
PHARM.AS income_statement (annual, 2025-12-31) — Other Special Charges: -3877000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Payables: 14588000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Payables: 14588000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 105900000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 105900000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Prepaid Assets: 6263000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 6263000.00
PHARM.AS income_statement (annual, 2025-12-31) — Pretax Income: 12847000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Pretax Income: 4800000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 19813000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 5249000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Properties: 0.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
PHARM.AS cash_flow (annual, 2025-12-31) — Purchase Of Business: -58215000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Purchase Of Business: -8000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -6000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Purchase Of Intangibles: 0.00
PHARM.AS cash_flow (annual, 2025-12-31) — Purchase Of Investment: -2000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -2000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Raw Materials: 0.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Raw Materials: 0.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Receivables: 48441000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Receivables: 48441000.00
PHARM.AS income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 43493000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 21100000.00
PHARM.AS income_statement (annual, 2025-12-31) — Reconciled Depreciation: 11216000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 3206000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Repayment Of Debt: -4245000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -1368000.00
PHARM.AS income_statement (annual, 2025-12-31) — Research And Development: 100367000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Research And Development: 32100000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Restricted Cash: 761000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Restricted Cash: 761000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Retained Earnings: -272983000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -272983000.00
PHARM.AS income_statement (annual, 2025-12-31) — Salaries And Wages: 92506000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Sale Of Investment: 85225000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 235000.00
PHARM.AS income_statement (annual, 2025-12-31) — Selling And Marketing Expense: 6655000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 31300000.00
PHARM.AS income_statement (annual, 2025-12-31) — Selling General And Administration: 117435000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Selling General And Administration: 51300000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Share Issued: 701680440.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Share Issued: 701680440.00
PHARM.AS income_statement (annual, 2025-12-31) — Special Income Charges: 3386000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Stock Based Compensation: 13766000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 4510000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Stockholders Equity: 277102000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 277102000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Tangible Book Value: 141564000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 141564000.00
PHARM.AS income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -385452.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
PHARM.AS income_statement (annual, 2025-12-31) — Tax Provision: 10310000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Tax Provision: -500000.00
PHARM.AS income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.26
PHARM.AS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.26
PHARM.AS balance_sheet (annual, 2025-12-31) — Taxes Receivable: 4742000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 4742000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Taxes Refund Paid: -4599000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Taxes Refund Paid: 867000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Total Assets: 499963000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Total Assets: 499963000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Total Capitalization: 369821000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 369821000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Total Debt: 115775000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Total Debt: 115775000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 277102000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 277102000.00
PHARM.AS income_statement (annual, 2025-12-31) — Total Expenses: 355253000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Total Expenses: 104500000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 222861000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 222861000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 200495000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 200495000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 107070000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 107070000.00
PHARM.AS income_statement (annual, 2025-12-31) — Total Operating Income As Reported: 25842000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: 6200000.00
PHARM.AS income_statement (annual, 2025-12-31) — Total Other Finance Cost: 196000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Total Tax Payable: 6043000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 6043000.00
PHARM.AS income_statement (annual, 2025-12-31) — Total Unusual Items: -1494000.00
PHARM.AS income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -1494000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Work In Process: 46688000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Work In Process: 46688000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Working Capital: 183678000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Working Capital: 183678000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — +Operating Expense: 71091000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — +Total Revenue: 72447000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 103526000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 60034000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 518601000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 744714286.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Basic EPS: -0.01
PHARM.AS cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 145305000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -238000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Capital Expenditure Reported: -238000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 17440000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 8065000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 52379000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 170175000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Cash Dividends Paid: 0.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: -9222000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -84760000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: 1951000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Change In Inventory: -264000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: -181000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Change In Payable: 5285000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: 5285000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Change In Receivables: -4395000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Change In Working Capital: 445000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Changes In Cash: -92031000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Common Stock: 8065000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 268960000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 6644000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Current Assets: 295511000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 2770000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Current Debt: 5375000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 8145000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 112346000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 675000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Depreciation: 3116000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 3116000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 3116000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 744714286.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.01
PHARM.AS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -5213000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — EBIT: -2058000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — EBITDA: 1058000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Earnings From Equity Interest: -385000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Earnings Losses From Equity Investments: 385000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: -895000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — End Cash Position: 52379000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 6580000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: -9222000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Free Cash Flow: 1714000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Gain Loss On Sale Of PPE: 6000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: 23749000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 15217000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 130988000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 23098000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Gross Profit: 65803000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Interest Expense: 2695000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 2695000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Interest Income: 3237000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 3237000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Interest Paid Cff: -125000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Interest Received Cfo: 379000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Inventory: 64577000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 367725000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -84760000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 6580000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 8113000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 14670000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 93390000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 108060000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -12975000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 1533000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Minority Interest: 0.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Minority Interests: 0.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Net Business Purchase And Sale: 0.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Net Debt: 46386000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Net Income: -5213000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -5213000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -5213000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -5213000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -5213000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -4753000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -5213000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Net Intangibles Purchase And Sale: 0.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Net Interest Income: 542000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: -84522000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -12975000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -12975000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 542000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Net PPE: 23098000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 137972000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Assets: 30668000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 30668000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 93000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 1058000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Normalized Income: -5213000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: 1952000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: 391000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Operating Income: -5288000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Operating Revenue: 72447000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 706252300.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Other Current Borrowings: 5375000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: 23749000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Other Gand A: 15217000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Other Income Expense: -8000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: -567000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 894000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: -1000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 377000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Other Properties: 23098000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 117796000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Payables: 103526000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 103526000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Pretax Income: -4753000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 3878000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Purchase Of Business: 0.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Purchase Of Intangibles: 0.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: -102646000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Receivables: 60034000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 6644000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 3116000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -12975000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Research And Development: 25557000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 725000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -281455000.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 18124000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 30317000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Selling General And Administration: 45534000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Share Issued: 706252300.00
PHARM.AS cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 3225000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 268960000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 137972000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Tax Provision: 459000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
PHARM.AS cash_flow (quarterly, 2026-03-31) — Taxes Refund Paid: -284000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Total Assets: 489365000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 362350000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Total Debt: 116205000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 268960000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Total Expenses: 77735000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 220405000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 193854000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 108059000.00
PHARM.AS income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -4911000.00
PHARM.AS balance_sheet (quarterly, 2026-03-31) — Working Capital: 183165000.00
PHAT balance_sheet (annual, 2021-12-31) — Construction In Progress: 0.00
PHAT income_statement (annual, 2021-12-31) — General And Administrative Expense: 62742000.00
PHAT cash_flow (annual, 2021-12-31) — Long Term Debt Payments: -54125000.00
PHAT income_statement (annual, 2021-12-31) — Other Gand A: 62742000.00
PHAT balance_sheet (annual, 2021-12-31) — Prepaid Assets: 3267000.00
PHAT cash_flow (annual, 2021-12-31) — Repayment Of Debt: -54125000.00
PHAT income_statement (annual, 2022-12-31) — +Operating Expense: 172440000.00
PHAT income_statement (annual, 2022-12-31) — +Total Revenue: 0.00
PHAT balance_sheet (annual, 2022-12-31) — Accounts Payable: 9997000.00
PHAT balance_sheet (annual, 2022-12-31) — Accounts Receivable: 0.00
PHAT balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -1471000.00
PHAT balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 652276000.00
PHAT income_statement (annual, 2022-12-31) — Basic Average Shares: 39118215.00
PHAT income_statement (annual, 2022-12-31) — Basic EPS: -5.05
PHAT cash_flow (annual, 2022-12-31) — Beginning Cash Position: 183419000.00
PHAT balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 2287000.00
PHAT cash_flow (annual, 2022-12-31) — Capital Expenditure: -1041000.00
PHAT balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 1806000.00
PHAT balance_sheet (annual, 2022-12-31) — Capital Stock: 3000.00
PHAT balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 155385000.00
PHAT balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 155385000.00
PHAT cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 120042000.00
PHAT cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -1041000.00
PHAT cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -146530000.00
PHAT cash_flow (annual, 2022-12-31) — Change In Account Payable: 8679000.00
PHAT cash_flow (annual, 2022-12-31) — Change In Accrued Expense: -1025000.00
PHAT cash_flow (annual, 2022-12-31) — Change In Interest Payable: 377000.00
PHAT cash_flow (annual, 2022-12-31) — Change In Inventory: 0.00
PHAT cash_flow (annual, 2022-12-31) — Change In Other Current Assets: -118000.00
PHAT cash_flow (annual, 2022-12-31) — Change In Other Working Capital: -238000.00
PHAT cash_flow (annual, 2022-12-31) — Change In Payable: 8679000.00
PHAT cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: 7654000.00
PHAT cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: -1860000.00
PHAT cash_flow (annual, 2022-12-31) — Change In Receivables: 0.00
PHAT cash_flow (annual, 2022-12-31) — Change In Working Capital: 5438000.00
PHAT cash_flow (annual, 2022-12-31) — Changes In Account Receivables: 0.00
PHAT cash_flow (annual, 2022-12-31) — Changes In Cash: -27529000.00
PHAT balance_sheet (annual, 2022-12-31) — Common Stock: 3000.00
PHAT balance_sheet (annual, 2022-12-31) — Common Stock Equity: -74814000.00
PHAT cash_flow (annual, 2022-12-31) — Common Stock Issuance: 24596000.00
PHAT balance_sheet (annual, 2022-12-31) — Construction In Progress: 399000.00
PHAT income_statement (annual, 2022-12-31) — Cost Of Revenue: 0.00
PHAT balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 7085000.00
PHAT balance_sheet (annual, 2022-12-31) — Current Assets: 160512000.00
PHAT balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 708000.00
PHAT balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 708000.00
PHAT balance_sheet (annual, 2022-12-31) — Current Liabilities: 26237000.00
PHAT cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 620000.00
PHAT cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 620000.00
PHAT income_statement (annual, 2022-12-31) — Diluted Average Shares: 39118215.00
PHAT income_statement (annual, 2022-12-31) — Diluted EPS: -5.05
PHAT income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -197723000.00
PHAT income_statement (annual, 2022-12-31) — EBIT: -170418000.00
PHAT income_statement (annual, 2022-12-31) — EBITDA: -169798000.00
PHAT cash_flow (annual, 2022-12-31) — End Cash Position: 155890000.00
PHAT cash_flow (annual, 2022-12-31) — Financing Cash Flow: 120042000.00
PHAT cash_flow (annual, 2022-12-31) — Free Cash Flow: -147571000.00
PHAT income_statement (annual, 2022-12-31) — General And Administrative Expense: 100999000.00
PHAT balance_sheet (annual, 2022-12-31) — Gross PPE: 4965000.00
PHAT income_statement (annual, 2022-12-31) — Gross Profit: 0.00
PHAT income_statement (annual, 2022-12-31) — Interest Expense: 27305000.00
PHAT income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 27305000.00
PHAT income_statement (annual, 2022-12-31) — Interest Income: 2132000.00
PHAT income_statement (annual, 2022-12-31) — Interest Income Non Operating: 2132000.00
PHAT cash_flow (annual, 2022-12-31) — Interest Paid Supplemental Data: 7033000.00
PHAT balance_sheet (annual, 2022-12-31) — Interest Payable: 854000.00
PHAT balance_sheet (annual, 2022-12-31) — Inventory: 0.00
PHAT balance_sheet (annual, 2022-12-31) — Invested Capital: 20450000.00
PHAT cash_flow (annual, 2022-12-31) — Investing Cash Flow: -1041000.00
PHAT cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 24596000.00
PHAT cash_flow (annual, 2022-12-31) — Issuance Of Debt: 0.00
PHAT balance_sheet (annual, 2022-12-31) — Leases: 115000.00
PHAT balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 1098000.00
PHAT balance_sheet (annual, 2022-12-31) — Long Term Debt: 95264000.00
PHAT balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 96362000.00
PHAT cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 0.00
PHAT cash_flow (annual, 2022-12-31) — Long Term Debt Payments: 0.00
PHAT balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 2164000.00
PHAT cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 24596000.00
PHAT income_statement (annual, 2022-12-31) — Net Income: -197723000.00
PHAT income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -197723000.00
PHAT income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -197723000.00
PHAT income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -197723000.00
PHAT income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -197723000.00
PHAT cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -197723000.00
PHAT income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -197723000.00
PHAT income_statement (annual, 2022-12-31) — Net Interest Income: -25173000.00
PHAT cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: 0.00
PHAT cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: 0.00
PHAT income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -25173000.00
PHAT cash_flow (annual, 2022-12-31) — Net Other Financing Charges: 95446000.00
PHAT balance_sheet (annual, 2022-12-31) — Net PPE: 3494000.00
PHAT cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -1041000.00
PHAT balance_sheet (annual, 2022-12-31) — Net Tangible Assets: -74814000.00
PHAT income_statement (annual, 2022-12-31) — Normalized EBITDA: -169798000.00
PHAT income_statement (annual, 2022-12-31) — Normalized Income: -197723000.00
PHAT cash_flow (annual, 2022-12-31) — Operating Cash Flow: -146530000.00
PHAT income_statement (annual, 2022-12-31) — Operating Income: -172440000.00
PHAT income_statement (annual, 2022-12-31) — Operating Revenue: 0.00
PHAT balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 41468871.00
PHAT balance_sheet (annual, 2022-12-31) — Other Current Assets: 5127000.00
PHAT income_statement (annual, 2022-12-31) — Other Gand A: 100999000.00
PHAT income_statement (annual, 2022-12-31) — Other Income Expense: -110000.00
PHAT cash_flow (annual, 2022-12-31) — Other Non Cash Items: 21002000.00
PHAT balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 804000.00
PHAT balance_sheet (annual, 2022-12-31) — Other Non Current Liabilities: 117025000.00
PHAT income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: -110000.00
PHAT balance_sheet (annual, 2022-12-31) — Other Properties: 2287000.00
PHAT balance_sheet (annual, 2022-12-31) — Payables: 9997000.00
PHAT balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 17082000.00
PHAT balance_sheet (annual, 2022-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 8447000.00
PHAT balance_sheet (annual, 2022-12-31) — Preferred Stock: 0.00
PHAT balance_sheet (annual, 2022-12-31) — Prepaid Assets: 5127000.00
PHAT income_statement (annual, 2022-12-31) — Pretax Income: -197723000.00
PHAT cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 0.00
PHAT balance_sheet (annual, 2022-12-31) — Properties: 0.00
PHAT cash_flow (annual, 2022-12-31) — Purchase Of PPE: -1041000.00
PHAT balance_sheet (annual, 2022-12-31) — Receivables: 0.00
PHAT income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 0.00
PHAT income_statement (annual, 2022-12-31) — Reconciled Depreciation: 620000.00
PHAT cash_flow (annual, 2022-12-31) — Repayment Of Debt: 0.00
PHAT income_statement (annual, 2022-12-31) — Research And Development: 71441000.00
PHAT balance_sheet (annual, 2022-12-31) — Retained Earnings: -727093000.00
PHAT income_statement (annual, 2022-12-31) — Selling General And Administration: 100999000.00
PHAT balance_sheet (annual, 2022-12-31) — Share Issued: 41468890.00
PHAT cash_flow (annual, 2022-12-31) — Stock Based Compensation: 24133000.00
PHAT balance_sheet (annual, 2022-12-31) — Stockholders Equity: -74814000.00
PHAT balance_sheet (annual, 2022-12-31) — Tangible Book Value: -74814000.00
PHAT income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
PHAT income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.00
PHAT balance_sheet (annual, 2022-12-31) — Total Assets: 164810000.00
PHAT balance_sheet (annual, 2022-12-31) — Total Capitalization: 20450000.00
PHAT balance_sheet (annual, 2022-12-31) — Total Debt: 97070000.00
PHAT balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: -74814000.00
PHAT income_statement (annual, 2022-12-31) — Total Expenses: 172440000.00
PHAT balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 239624000.00
PHAT balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 4298000.00
PHAT balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 213387000.00
PHAT income_statement (annual, 2022-12-31) — Total Operating Income As Reported: -172440000.00
PHAT balance_sheet (annual, 2022-12-31) — Treasury Shares Number: 19.00
PHAT balance_sheet (annual, 2022-12-31) — Treasury Stock: 0.00
PHAT balance_sheet (annual, 2022-12-31) — Working Capital: 134275000.00
PHAT income_statement (annual, 2023-12-31) — +Operating Expense: 167827000.00
PHAT income_statement (annual, 2023-12-31) — +Total Revenue: 682000.00
PHAT balance_sheet (annual, 2023-12-31) — Accounts Payable: 12601000.00
PHAT balance_sheet (annual, 2023-12-31) — Accounts Receivable: 1637000.00
PHAT balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -2046000.00
PHAT balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 855921000.00
PHAT income_statement (annual, 2023-12-31) — Basic Average Shares: 51289092.00
PHAT income_statement (annual, 2023-12-31) — Basic EPS: -3.93
PHAT cash_flow (annual, 2023-12-31) — Beginning Cash Position: 155890000.00
PHAT balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 1475000.00
PHAT cash_flow (annual, 2023-12-31) — Capital Expenditure: -1634000.00
PHAT balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 1188000.00
PHAT balance_sheet (annual, 2023-12-31) — Capital Stock: 5000.00
PHAT balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 381393000.00
PHAT balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 381393000.00
PHAT cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: 367580000.00
PHAT cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: -1634000.00
PHAT cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -137580000.00
PHAT cash_flow (annual, 2023-12-31) — Change In Account Payable: 6410000.00
PHAT cash_flow (annual, 2023-12-31) — Change In Accrued Expense: 292000.00
PHAT cash_flow (annual, 2023-12-31) — Change In Interest Payable: 292000.00
PHAT cash_flow (annual, 2023-12-31) — Change In Inventory: -9442000.00
PHAT cash_flow (annual, 2023-12-31) — Change In Other Current Assets: -1394000.00
PHAT cash_flow (annual, 2023-12-31) — Change In Other Working Capital: 194000.00
PHAT cash_flow (annual, 2023-12-31) — Change In Payable: 6410000.00
PHAT cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 6702000.00
PHAT cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: -8067000.00
PHAT cash_flow (annual, 2023-12-31) — Change In Receivables: -1637000.00
PHAT cash_flow (annual, 2023-12-31) — Change In Working Capital: -13644000.00
PHAT cash_flow (annual, 2023-12-31) — Changes In Account Receivables: -1637000.00
PHAT cash_flow (annual, 2023-12-31) — Changes In Cash: 228366000.00
PHAT balance_sheet (annual, 2023-12-31) — Common Stock: 5000.00
PHAT balance_sheet (annual, 2023-12-31) — Common Stock Equity: -72759000.00
PHAT cash_flow (annual, 2023-12-31) — Common Stock Issuance: 155463000.00
PHAT balance_sheet (annual, 2023-12-31) — Construction In Progress: 0.00
PHAT income_statement (annual, 2023-12-31) — Cost Of Revenue: 167000.00
PHAT balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 5025000.00
PHAT balance_sheet (annual, 2023-12-31) — Current Assets: 397432000.00
PHAT balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 726000.00
PHAT balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 726000.00
PHAT balance_sheet (annual, 2023-12-31) — Current Liabilities: 38781000.00
PHAT cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 575000.00
PHAT cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 575000.00
PHAT income_statement (annual, 2023-12-31) — Diluted Average Shares: 51289092.00
PHAT income_statement (annual, 2023-12-31) — Diluted EPS: -3.93
PHAT income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -201592000.00
PHAT income_statement (annual, 2023-12-31) — EBIT: -159624000.00
PHAT income_statement (annual, 2023-12-31) — EBITDA: -159049000.00
PHAT cash_flow (annual, 2023-12-31) — End Cash Position: 384256000.00
PHAT cash_flow (annual, 2023-12-31) — Financing Cash Flow: 367580000.00
PHAT balance_sheet (annual, 2023-12-31) — Finished Goods: 647000.00
PHAT cash_flow (annual, 2023-12-31) — Free Cash Flow: -139214000.00
PHAT balance_sheet (annual, 2023-12-31) — Gross PPE: 5667000.00
PHAT income_statement (annual, 2023-12-31) — Gross Profit: 515000.00
PHAT income_statement (annual, 2023-12-31) — Interest Expense: 41968000.00
PHAT income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 41968000.00
PHAT income_statement (annual, 2023-12-31) — Interest Income: 7876000.00
PHAT income_statement (annual, 2023-12-31) — Interest Income Non Operating: 7876000.00
PHAT cash_flow (annual, 2023-12-31) — Interest Paid Supplemental Data: 11133000.00
PHAT balance_sheet (annual, 2023-12-31) — Interest Payable: 1146000.00
PHAT balance_sheet (annual, 2023-12-31) — Inventory: 1208000.00
PHAT balance_sheet (annual, 2023-12-31) — Invested Capital: 65083000.00
PHAT cash_flow (annual, 2023-12-31) — Investing Cash Flow: -1634000.00
PHAT cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 155463000.00
PHAT cash_flow (annual, 2023-12-31) — Issuance Of Debt: 39318000.00
PHAT balance_sheet (annual, 2023-12-31) — Leases: 139000.00
PHAT balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 462000.00
PHAT balance_sheet (annual, 2023-12-31) — Long Term Debt: 137842000.00
PHAT balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 138304000.00
PHAT cash_flow (annual, 2023-12-31) — Long Term Debt Issuance: 39318000.00
PHAT balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 2566000.00
PHAT cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 155463000.00
PHAT income_statement (annual, 2023-12-31) — Net Income: -201592000.00
PHAT income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -201592000.00
PHAT income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -201592000.00
PHAT income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -201592000.00
PHAT income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -201592000.00
PHAT cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -201592000.00
PHAT income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -201592000.00
PHAT income_statement (annual, 2023-12-31) — Net Interest Income: -34092000.00
PHAT cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: 39318000.00
PHAT cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: 39318000.00
PHAT income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -34092000.00
PHAT cash_flow (annual, 2023-12-31) — Net Other Financing Charges: 172675000.00
PHAT balance_sheet (annual, 2023-12-31) — Net PPE: 3621000.00
PHAT cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -1634000.00
PHAT balance_sheet (annual, 2023-12-31) — Net Tangible Assets: -72759000.00
PHAT income_statement (annual, 2023-12-31) — Normalized EBITDA: -159049000.00
PHAT income_statement (annual, 2023-12-31) — Normalized Income: -201592000.00
PHAT cash_flow (annual, 2023-12-31) — Operating Cash Flow: -137580000.00
PHAT income_statement (annual, 2023-12-31) — Operating Income: -167312000.00
PHAT income_statement (annual, 2023-12-31) — Operating Revenue: 682000.00
PHAT balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 57970044.00
PHAT balance_sheet (annual, 2023-12-31) — Other Current Assets: 13194000.00
PHAT balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 7111000.00
PHAT income_statement (annual, 2023-12-31) — Other Income Expense: -188000.00
PHAT cash_flow (annual, 2023-12-31) — Other Non Cash Items: 32056000.00
PHAT balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 12789000.00
PHAT balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 309516000.00
PHAT income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: -188000.00
PHAT balance_sheet (annual, 2023-12-31) — Other Properties: 1487000.00
PHAT balance_sheet (annual, 2023-12-31) — Payables: 12601000.00
PHAT balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 17626000.00
PHAT balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 13318000.00
PHAT balance_sheet (annual, 2023-12-31) — Preferred Stock: 0.00
PHAT income_statement (annual, 2023-12-31) — Pretax Income: -201592000.00
PHAT cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 124000.00
PHAT balance_sheet (annual, 2023-12-31) — Properties: 0.00
PHAT cash_flow (annual, 2023-12-31) — Provisionand Write Offof Assets: 0.00
PHAT cash_flow (annual, 2023-12-31) — Purchase Of PPE: -1634000.00
PHAT balance_sheet (annual, 2023-12-31) — Raw Materials: 561000.00
PHAT balance_sheet (annual, 2023-12-31) — Receivables: 1637000.00
PHAT income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 167000.00
PHAT income_statement (annual, 2023-12-31) — Reconciled Depreciation: 575000.00
PHAT income_statement (annual, 2023-12-31) — Research And Development: 49899000.00
PHAT balance_sheet (annual, 2023-12-31) — Retained Earnings: -928685000.00
PHAT income_statement (annual, 2023-12-31) — Selling General And Administration: 117928000.00
PHAT balance_sheet (annual, 2023-12-31) — Share Issued: 57970063.00
PHAT cash_flow (annual, 2023-12-31) — Stock Based Compensation: 45025000.00
PHAT balance_sheet (annual, 2023-12-31) — Stockholders Equity: -72759000.00
PHAT balance_sheet (annual, 2023-12-31) — Tangible Book Value: -72759000.00
PHAT income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 0.00